H.R. 7384 118th Congress
Creating Hope Reauthorization Act of 2024
- Health
- Sponsor: Rep. McCaul, Michael T. [R-TX-10]
- Congress.gov ↗
Latest action, Feb 16, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
66 cosponsors
Sponsored by Rep. McCaul, Michael T. [R-TX-10] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
38 D · 28 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
ACADIA PHARMACEUTICALS, INC.
TIBER CREEK GROUP
4 reports
4 reports
4 reports
CHIESI USA, INC.
SPLITOAK STRATEGIES LLC
4 reports
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)
NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
4 reports
PRAXIS PRECISION MEDICINES
THE KPM GROUP DC LLC
4 reports
4 reports
RARE DISEASE COMPANY COALITION
THE KPM GROUP DC LLC
4 reports
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
4 reports
ALLIANCE FOR REGENERATIVE MEDICINE
AVENUE SOLUTIONS
3 reports
3 reports
The top 25 of 40 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS | 4 | $1.4M | Q1 2024 | Q3 2024 | yes | |
| ACADIA PHARMACEUTICALS, INC. | TIBER CREEK GROUP | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | 4 | $8.1M | Q1 2024 | Q3 2024 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | 4 | $1.3M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 4 | $1.0M | Q1 2024 | Q3 2024 | yes | |
| BRIDGEBIO PHARMA, INC. | 4 | $830K | Q1 2024 | Q3 2024 | yes | |
| CHIESI USA, INC. | SPLITOAK STRATEGIES LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) | NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES | 4 | $5.7M | Q1 2024 | Q3 2024 | yes |
| PRAXIS PRECISION MEDICINES | THE KPM GROUP DC LLC | 4 | $120K | Q1 2024 | Q3 2024 | yes |
| PTC THERAPEUTICS, INC. | 4 | $760K | Q1 2024 | Q3 2024 | yes | |
| RARE DISEASE COMPANY COALITION | THE KPM GROUP DC LLC | 4 | $560K | Q1 2024 | Q3 2024 | yes |
| RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) | 4 | $120K | Q1 2024 | Q3 2024 | yes | |
| ALLIANCE FOR REGENERATIVE MEDICINE | AVENUE SOLUTIONS | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 3 | $750K | Q4 2024 | Q3 2024 | yes | |
| BAYER CORPORATION (CONSOLIDATED REPORT) | 3 | $6.2M | Q4 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AKIN GUMP STRAUSS HAUER & FELD | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| CURE SMA | 3 | $225K | Q4 2024 | Q3 2024 | yes | |
| GENETIX BIOTHERAPEUTICS, INC. | ARNOLD & PORTER KAYE SCHOLER LLP | 3 | $180K | Q4 2024 | Q3 2024 | yes |
| HARMONY BIOSCIENCES | 3 | $450K | Q4 2024 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 3 | $5.0M | Q4 2024 | Q3 2024 | yes | |
| MUSCULAR DYSTROPHY ASSOCIATION, INC. | 3 | $210K | Q4 2024 | Q3 2024 | yes | |
| NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | ARTEMIS POLICY GROUP LLC | 3 | $150K | Q4 2024 | Q3 2024 | yes |
| TRAVERE THERAPEUTICS | 3 | $360K | Q4 2024 | Q3 2024 | yes | |
| ALLIANCE FOR REGENERATIVE MEDICINE | 2 | $350K | Q4 2024 | Q3 2024 | yes |